Sorensen MD, Eisner BH, Stone KL, Kahn AJ, Lui LY, Sadetsky N, Stoller ML
Tirzepatide has demonstrated approximately 11.917.8% greater weight loss than placebo over 72 weeks, semaglutide about 12.4% greater weight loss over 68 weeks, and liraglutide around 8.0% weight reduction compared with placebo over 56 weeks
It usually forms in tendons, ligaments, and cartilage
Both medications warn about possible complications in individuals with diabetic retinopathy and suggest close monitoring for those with a history of this eye condition
Beyond skin-related effects, GHK-Cu is being studied for its anti-inflammatory and antioxidant activity, helping reduce oxidative stress and support healthier cellular function
A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity.Journal of obesity, 2024, Dr